Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/201028 International Application No.: PCT/US2018/029915
Publication Date: 01.11.2018 International Filing Date: 27.04.2018
G01N 33/50 (2006.01) ,G01N 33/68 (2006.01) ,G01N 33/574 (2006.01) ,A61K 39/395 (2006.01) ,A61K 35/763 (2015.01)
[IPC code unknown for G01N 33/50][IPC code unknown for G01N 33/68][IPC code unknown for G01N 33/574][IPC code unknown for A61K 39/395][IPC code unknown for A61K 35/763]
MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue Rahway, NJ 07065, US
AMGEN INC. [US/US]; One Amgen Center Drive Thousand Oaks, CA 91320, US
GANSERT, Jennifer Lorraine; US
ANDERSON, Abraham Antonio; US
JAVIER, Teofilo; US
BARTON, Steven, K.; US
ANIS, Hissan; US
BARONE, Stephen, B.; US
AREZINA, Vladimir, I.; US
Priority Data:
(EN) Biomarkers useful for identifying a variety of cancers that are responsive to treatment with a combination therapy comprising pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof and talimogene laherparepvec are provided. Methods of treating cancers that are resistant to monotherapy with pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof are provided. Methods of treating a cancer in a subject having a tumor with a low CD8+ density, a low or negative interferon gamma signature, and/or a low or negative PD-L1 status are also provided.
(FR) L'invention concerne des biomarqueurs utiles pour identifier divers cancers qui sont sensibles au traitement par une polythérapie à base de pembrolizumab, d'un variant ou fragment de celui-ci se liant à l'antigène et de talimogène laherparepvec. L'invention concerne également des méthodes de traitement des cancers qui sont résistants à la monothérapie à base de pembrolizumab, d'un variant ou un fragment de celui-ci se liant à l'antigène. Des méthodes de traitement d'un cancer chez un sujet ayant une tumeur caractérisée par une faible densité de CD8+, une signature d'interféron gamma faible ou négative et/ou un état PD-L1 faible ou négatif sont en outre décrites.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)